Skip to main content
Clinical Trials/NCT04448171
NCT04448171TerminatedNot Applicable

Transcutaneous Electric Nerve Stimulation For Pain Control During Office Intra-detrusor Onabotulinumtoxin A Cystoscopy Injection for Overactive Bladder: A Phase III Randomized Controlled Trial

Mayo Clinic2 sites in 1 country42 target enrollmentStarted: October 28, 2020Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Terminated
Enrollment
42
Locations
2
Primary Endpoint
Change in Participant Reported Pain Score From Baseline to Intra-Procedure

Study Overview

Brief Summary

The purpose of this study is to determine how Transcutaneous Electric Nerve Stimulation (TENS) units affects pain management during office cystoscopic Botox injections and patient satisfaction with the procedure .

Detailed Description

Overactive bladder (OAB) is a symptom complex pronounced by urinary urgency, affecting up to 12% of the adult population, with a significant negative impact quality on the life. Cystoscopic intra-detrusor onabotulinumtoxin A is used for the treatment of OAB in participants who do not tolerate or adequately respond to oral anticholinergic medications. The response to the onabotulinumtoxin A injection is transient and requires repeat injections roughly every 6-7 months. Adequate pain control during this procedure is essential for success in the office setting.

Options for adequate pain control during office-based cystoscopy procedures are limited. Currently, varying pain control strategies are being used including local anesthesia (intra-urethral lidocaine, intra-vesicular lidocaine solution), distraction techniques (conversation/music/'squeeze balls'), aromatherapy, intramuscular analgesia, sedation and a combination of these techniques. Despite this, participants often experience pain during the procedure. Trans-cutaneous Electrical Nerve Stimulation (TENS) is a non-pharmacologic, non-invasive and safe method of pain control that involves delivery of electrical impulses to the skin, resulting in a reduction in perceived pain. TENS units have been successfully used for procedural pain management during office hysteroscopy and office colonoscopy. TENS may also help reduce pain during office cystoscopy.

The study is a two arm phase III double-blind, randomized, placebo-controlled trial looking at the effect of TENS unit on pain in participants receiving office based cystoscopic onabotulinum toxin A injection for overactive bladder at the Mayo Clinic in Rochester, Minnesota.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Triple (Participant, Investigator, Outcomes Assessor)

Masking Description

The participant, the physician administering the Botox, and the study coordinator (outcomes assessor) assigned to the study will be blinded to the randomization. Both groups of participants will receive the TENS unit electrode placement by the assigned clinical nurse who is not blinded.

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
Female
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Females age 18 years or older
  • Scheduled to receive intra-detrusor Onabotulinumtoxin-A injection for Overactive Bladder in the outpatient clinic
  • Reads, speaks, and understands the English language
  • Able to understand the requirements of the study, including randomization
  • Willing and able to provide written informed consent

Exclusion Criteria

  • Previous use of TENS therapy within one year prior to study enrollment
  • Allergy to adhesives
  • Currently has an implanted pacemaker or automatic cardiac defibrillator
  • History of epilepsy
  • Currently pregnant or within 12 weeks postpartum
  • Unwilling to be randomized

Outcomes

Primary Outcomes

Change in Participant Reported Pain Score From Baseline to Intra-Procedure

Time Frame: Baseline; intra-procedure

Using the participant-reported numerical pain scale, the change in participant reported pain was measured. This change was measured between two time points, baseline and intra-procedure. The participant-reported pain scale ranges from 0 (no pain) to 10 (worst pain) with higher scores indicating worse pain. When analyzing the data, the scale was multiplied by a factor of 10 to get a 100-point scale. Final results are reported using the 100-point scale ranging from 0 (no pain) to 100 (worst pain) with higher scores indicating worse pain.

Secondary Outcomes

  • Change in Participant Satisfaction From Post Procedure to 10 Minutes Following Completion of Cystoscopy(Postprocedure, 10 minutes following completion of cystoscopy)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

John A. Occhino

Associate Professor of Obstetrics and Gynecology

Mayo Clinic

Study Sites (2)

Loading locations...

Similar Trials